ACT-CTU Clinical Trial Rounds - Dr. Gustavo Duque - January 1, 2026

Value of the Information & Strength of the Argument

The presentation provides valuable insights into the emerging field of geroscience, clearly explaining its core concepts and potential clinical applications. The argumentation is well-structured, building from basic biology to clinical trial design. Dr. Duque supports his points with references to key publications and his own research, though some claims would benefit from more detailed evidence. The discussion of challenges and future directions is particularly valuable for researchers and clinicians in the field.

Scientific Rigor, Source Quality, Title Accuracy

The talk demonstrates scientific rigor by referencing established concepts and recent literature, such as the hallmarks of aging and the translational geroscience network. The sources cited are credible, including publications by Brian Kennedy and Carlos Lopez-Otin. The title accurately reflects the content, focusing on the development of a geroscience clinical trial unit. The presentation is based on the speaker’s expertise and ongoing research, but lacks detailed methodological descriptions and independent verification of the presented findings.

The title accurately reflects the content: a clinical trial rounds presentation on building a geroscience clinical trial unit.

8/10

Presentation by a recognized expert in geroscience, with references to established concepts and recent publications. The talk is based on the speaker's own research and reviews of the field, but lacks detailed methodological descriptions and independent verification.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 02:00Introduction to geroscience concept and its origins at the NIA.
• 05:00Explanation of the hallmarks of aging and their role in age-related diseases.
• 10:00Discussion on healthspan vs. lifespan and the goals of geroscience.
• 15:00Examples of geroscience research: targeting fat in muscle and bone.
• 20:00Research on the kynurenine pathway and picolinic acid as potential therapy.
• 25:00Challenges in geroscience clinical trials: outcomes and regulatory issues.
• 30:00Introduction of the geroscience clinical trials unit at RI-MUHC.

• Geroscience: The Next Frontier — Mentioned as the origin of the geroscience concept.
• The Hallmarks of Aging — Referenced as the paper by Carlos Lopez-Otin et al. describing the hallmarks of aging.
• Translational Geroscience Network — Mentioned as the US network established in 2019.
• Canadian Translational Geroscience Network — Mentioned as the Canadian network chaired by Dr. Duque.

• The Hallmarks of Aging — Supports the concept of hallmarks of aging as described in the presentation.
• Geroscience: The Next Frontier — Aligns with the origin and goals of geroscience.

• Aging is not a disease: implications for geroscience — Presents a contrasting view on whether aging should be classified as a disease, a topic discussed in the presentation.